DALLAS, April 22, 2022 /PRNewswire/ -- Lantern Pharma
Inc. (NASDAQ: LTRN), a clinical stage
biopharmaceutical company using its proprietary RADR®
artificial intelligence (A.I.) and machine learning (ML) platform
to transform the cost, pace, and timeline of oncology drug
discovery and development, today announced that it will report its
first quarter 2022 financial results on Tuesday, May 3, 2022, after the financial markets
close. The company will host a conference call and webcast in a
webinar format at 4:30 p.m. Eastern
Time / 1:30 p.m. Pacific Time on
Tuesday, May 3, 2022.
Management intends to discuss the operating and financial
results for the first quarter ended March
31, 2022 and provide guidance on upcoming milestones.
Panna Sharma, President and Chief
Executive Officer of Lantern Pharma, will lead the call and will be
joined by other members of the management team.
To register for the webinar, please sign up here:
https://us06web.zoom.us/webinar/register/3516500329459/WN_fOeTQP8mRru_FxXFWsR69w
A replay of the webinar will be available on the investor
relations section of the Company's website:
ir.lanternpharma.com.
About Lantern Pharma
Lantern Pharma (NASDAQ: LTRN) is
a clinical-stage oncology-focused biopharmaceutical company
leveraging its proprietary RADR® A.I. and machine
learning platform to discover biomarker signatures that identify
patients most likely to respond to its pipeline of
genomically-targeted therapeutics. Lantern is currently developing
four drug candidates and an ADC program across nine disclosed tumor
targets, including two phase 2 programs. By targeting drugs to
patients whose genomic profile identifies them as having the
highest probability of benefiting from the drug, Lantern's approach
represents the potential to deliver best-in-class outcomes.
Contact:
Nicole Leber
Investor Relations Associate
ir@lanternpharma.com
Please find more information at:
Website: www.lanternpharma.com
LinkedIn: https://www.linkedin.com/company/lanternpharma/
Twitter: @lanternpharma
Forward-looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These forward-looking statements include, among other
things, statements relating to: future events or our future
financial performance; the potential advantages of our
RADR® platform in identifying drug candidates and
patient populations that are likely to respond to a drug candidate;
our strategic plans to advance the development of our drug
candidates and antibody drug conjugate (ADC) development program;
estimates regarding the development timing for our drug candidates
and ADC development program; our research and development efforts
of our internal drug discovery programs and the utilization of our
RADR® platform to streamline the drug development
process; our intention to leverage artificial intelligence, machine
learning and genomic data to streamline and transform the pace,
risk and cost of oncology drug discovery and development and to
identify patient populations that would likely respond to a drug
candidate; estimates regarding potential markets and potential
market sizes; sales estimates for our drug candidates and our plans
to discover and develop drug candidates and to maximize their
commercial potential by advancing such drug candidates ourselves or
in collaboration with others. Any statements that are not
statements of historical fact (including, without limitation,
statements that use words such as "anticipate," "believe,"
"contemplate," "could," "estimate," "expect," "intend," "seek,"
"may," "might," "plan," "potential," "predict," "project,"
"target," "objective," "aim," "upcoming," "should," "will,"
"would," or the negative of these words or other similar
expressions) should be considered forward-looking statements. There
are a number of important factors that could cause our actual
results to differ materially from those indicated by the
forward-looking statements, such as (i) the impact of the COVID-19
pandemic, (ii) the risk that our research and the research of our
collaborators may not be successful, (iii) the risk that none of
our product candidates has received FDA marketing approval, and we
may not be able to successfully initiate, conduct, or conclude
clinical testing for or obtain marketing approval for our product
candidates, (iv) the risk that no drug product based on our
proprietary RADR® A.I. platform has received FDA
marketing approval or otherwise been incorporated into a commercial
product, and (v) those other factors set forth in the Risk Factors
section in our Annual Report on Form 10-K for the year ended
December 31, 2021, filed with the
Securities and Exchange Commission on March
10, 2022. You may access our Annual Report on Form 10-K for
the year ended December 31, 2021
under the investor SEC filings tab of our website at
www.lanternpharma.com or on the SEC's website at www.sec.gov. Given
these risks and uncertainties, we can give no assurances that our
forward-looking statements will prove to be accurate, or that any
other results or events projected or contemplated by our
forward-looking statements will in fact occur, and we caution
investors not to place undue reliance on these statements. All
forward-looking statements in this press release represent our
judgment as of the date hereof, and, except as otherwise required
by law, we disclaim any obligation to update any forward-looking
statements to conform the statement to actual results or changes in
our expectations.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lantern-pharma-to-report-first-quarter-2022-operating--financial-results-on-may-3rd-2022-at-430-pm-et-301530545.html
SOURCE Lantern Pharma